



Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going?

The advent of precision medicine has revolutionized the therapeutic landscape of non-small cell lung cancer (NSCLC), leading to a significant increase of patients' life expectancy and quality of life, with a 5-year survival rate of 21.7% nowadays, compared to 17.2% ten years ago (1). Since the discovery of the *epidermal growth factor receptor (EGFR)* sensitizing mutations in 2004 (2), the number of targetable alterations detected in lung cancer patients has progressively increased, thus extending the percentage of potential candidates to personalized treatment strategies. Alongside *EGFR*, *BRAF* (*v-Raf murine sarcoma viral oncogene homolog B*), *KRAS* (*kirsten rat sarcoma 2 viral oncogene homolog*) and *c-MET* (*hepatocyte growth factor receptor*)-exon 14 mutations, different chromosomal rearrangements involving *ALK* (*anaplastic lymphoma kinase*), *ROS1* (*v-ros avian UR2 sarcoma virus oncogene homolog 1*), *RET* (*rearranged during transfection*), and *NTRK* (*tropomyosin receptor kinase A*) genes, have been recently identified as druggable targets in a relevant subgroup of metastatic NSCLC patients, with both old and new-generation tyrosine-kinase inhibitors (TKIs) already available or coming soon in the clinical setting (3). Crizotinib represented the first example of successful targeted therapy available for the treatment of metastatic NSCLC patients harboring either *ALK* or *ROS1* chromosomal rearrangements (4,5). The subsequent introduction of more effective and better tolerated second/third-generation TKIs into clinical practice has dramatically improved patients' outcomes (6-8), leading to unprecedented long-term survival, even compared with other oncogene-addicted NSCLC subgroups. The NTRK inhibitors Entrectinib (9) and Larotrectinib (10) were the first targeted agents receiving a tissue agnostic approval by the Food and Drug Administration (FDA), for the clinical treatment of patients with NTRK gene fusion positive advanced solid tumors, including lung cancer. More recently the community of thoracic oncologists has celebrated the advent of new selective TKIs effectively targeting RET-rearranged metastatic disease (11). Despite the great efficacy of the new generation TKIs available for the clinical treatment of a relevant subgroup of NSCLC patients harbouring oncogenic rearrangements, however the histological and biological heterogeneity are well-known phenomena with significant impact on patients' response and survival outcomes, thus questioning the best upfront TKI to be selected in order to delay the occurrence of disease progression. The series "Looking for chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions", published in *Translational Lung Cancer Research (TLCR)* addresses the actual and controversial topic of the best treatment sequences across the different subgroups of NSCLC harboring oncogenic fusions (*ALK*, *ROS1*, *RET*, *NTRK*, *NRG1*), including also the optimal strategies for the clinical management of oligo-metastatic/progressive diseases.

A deeper understanding of innate/acquired resistance to the different TKIs already available for clinical use and the development of new effective treatment strategies to overcome it, represent a current area of intense investigation and has been extensively debated within different papers published in the series.

Since we are now moving towards genomic-driven therapeutic sequences in order to identify the best candidate to tailored strategies (12), a non-invasive detection/monitoring of genomic alterations through circulating tumor DNA/RNA analysis is emerging as a reasonable approach to guide treatment decision during the disease course. Two different specific papers will discuss current evidence and technical issue related to both tissue and plasma genotyping methods for detecting oncogenic rearrangements in NSCLC patients. Finally the role of immune-checkpoint inhibitors in the treatment algorithm of fusion driven metastatic NSCLC, the potential application of targeted therapies in the early stage setting, as well as the future perspectives emerging from pre-clinical models, have been specifically discussed in dedicated literature reviews.

In conclusion the series "Looking for chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions" addresses the most relevant questions related to the clinical management of NSCLC patients harboring oncogenic rearrangements, reporting an updated and detailed overview of current available evidence and providing critical discussions by key experts in the field.

Acknowledgments

Funding: None.

Footnote

Provenance and Peer Review: This article was commissioned by the editorial office, *Translational Lung Cancer Research* for the series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions”. The article did not undergo external peer review.


Conflicts of Interest: Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/tlcr-2019-cnsclc-14>). The series “Looking for Chimeras in NSCLC: Widen Therapeutic Options Targeting Oncogenic Fusions” was commissioned by the editorial office without any funding or sponsorship. Both authors served as the unpaid Guest Editor of the series. SN serves as an unpaid editorial board member of *Translational Lung Cancer Research* from Jul 2014 to Jul 2021. SN reports personal fees from Eli Lilly, personal fees from MSD, personal fees from Roche, personal fees from BMS, personal fees from Takeda, personal fees from Pfizer, personal fees from Abbvie, personal fees from Celgene, personal fees from Astrazeneca, personal fees from Boehringer Ingelheim, outside the submitted work. Both authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

1. American Society of Clinical Oncology. 2019 State of Lung Cancer Report. Accessed 17 May 2020. Available online: <https://ascopost.com/news/november-2019/2019-state-of-lung-cancer-report-released/>
2. Paez JG, Jänne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. *Science* 2004;304:1497-500.
3. Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2018;29:iv192-iv237.
4. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. *N Engl J Med* 2013;368:2385-94.
5. Shaw AT, Ou SH, Bang YJ, et al. Crizotinib in ROS1-rearranged non-small-cell lung cancer. *N Engl J Med* 2014;371:1963-71.
6. Peters S, Camidge DR, Shaw AT, et al. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2017;377:829-38.
7. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2018;379:2027-39.
8. Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. *Lancet Oncol* 2018;19:1654-67.
9. Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials. *Lancet Oncol* 2020;21:271-82.
10. Hong DS, DuBois SG, Kummar S, et al. Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials. *Lancet Oncol* 2020;21:531-40.
11. Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. *N Engl J Med* 2020;383:813-24.
12. Shaw AT, Solomon BJ, Besse B, et al. ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol* 2019;37:1370-9.



Francesco Passiglia



Silvia Novello

Francesco Passiglia, Silvia Novello, MD, PhD*Department of Oncology, University of Turin, San Luigi Hospital, Orbassano, Italy.**(Email: francesco.passiglia@unito.it; silvia.novello@unito.it)*

Submitted Nov 02, 2020. Accepted for publication Dec 02, 2020.

doi: 10.21037/tlcr-2019-cnsclc-14

View this article at: <http://dx.doi.org/10.21037/tlcr-2019-cnsclc-14>

Cite this article as: Passiglia F, Novello S. Targeting chimeras fusion proteins in non-small cell lung cancer: where are we going? *Transl Lung Cancer Res* 2020;9(6):2518-2520. doi: 10.21037/tlcr-2019-cnsclc-14